[Safety of intraperitoneal chemotherapy with paclitaxel in gastric cancer patients with peritoneal dissemination].
We evaluated the safety of paclitaxel (TXL) via intraperitoneal (i.p.) administration in 6 patients with peritoneal dissemination of gastric cancer. Four patients were treated with TXL via i.p. administration at a dosage of 80-90 mg/m2 every 1 to 2 weeks. Grade 4 leukopenia was observed in 1 patient, accompanied with massive ascites. Two other patients, who also had malignant peritoneal effusion, were treated with TXL via i.p. administration at a dosage of 60 mg/m2 every 1 to 2 weeks. All toxicities were mild in those two patients. TXL via i.p. administration at a dosage of less than 90 mg/m2 has never been reported to cause a grade 4 leukopenia. These results suggest that a phase I/II study of TXL via i.p. administration should be tried in gastric cancer patients with malignant peritoneal effusion.
Fujitani
Kazumasa
K
Dept. of Surgery, Osaka National Hospital.
Hirao
Motohiro
M
Tsujinaka
Toshimasa
T
D000368:Aged; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D006801:Humans; D007263:Infusions, Parenteral; D008297:Male; D008875:Middle Aged; D009366:Neoplasm Seeding; D017239:Paclitaxel / Q000008:administration & dosage* / Q000009:adverse effects; D010534:Peritoneal Neoplasms / Q000188:drug therapy* / Q000556:secondary*; D012449:Safety; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000473:pathology*
D000972:Antineoplastic Agents, Phytogenic; D017239:Paclitaxel